Circulating microRNA after autologous bone marrow mononuclear cell (BM-MNC) injection in patients with ischemic stroke

2019 ◽  
Vol 68 (3) ◽  
pp. 807-810 ◽  
Author(s):  
Fernando Mancha ◽  
Irene Escudero-Martinez ◽  
Elena Zapata-Arriaza ◽  
Angela Vega-Salvatierra ◽  
Juan Antonio Cabezas ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Ischemic Stroke ◽  
Mononuclear Cell ◽  
Expression Patterns ◽  
Control Group ◽  
Bone Marrow Mononuclear Cell ◽  
Circulating Microrna ◽  
Unique Identifier ◽  
Circulating Mirna ◽  
Link Type

Previous studies have shown the potential of microRNAs (miRNA) in the pathological process of stroke and functional recovery. Bone marrow mononuclear cell (BM-MNC) transplantation improves recovery in experimental models of ischemic stroke that might be related with miRNA modifications. However, its effect on circulating miRNA has not been described in patients with stroke. We aimed to evaluate the circulating levels of miRNAs after autologous BM-MNC transplantation in patients with stroke. We investigate the pattern of miRNA-133b and miRNA-34a expression in patients with ischemic stroke included in a multicenter randomized controlled phase IIb trial (http://www.clinicaltrials.gov; unique identifier: NCT02178657). Patients were randomized to 2 different doses of autologous intra-arterial BM-MNC injection (2×106/kg or 5×106/kg) or control group within the first 7 days after stroke onset. We evaluate plasma concentration of miRNA-113b and miRNA-34a at inclusion and 4, 7, and 90 days after treatment. Thirteen cases (8 with 2×106/kg BM-MNC dose and 5 with 5×106/kg dose) and 11 controls (BM-MNC non-treated) were consecutively included. Mean age was 64.1±12.3 with a mean National Institutes of Health Stroke Scale score at inclusion of 14.5. Basal levels of miRNA were similar in both groups. miR-34a-5p and miR-133b showed different expression patterns. There was a significant dose-dependent increase of miRNA-34a levels 4 days after BM-MNC injection (fold change 3.7, p<0.001), whereas miRNA-133b showed a significant increase in the low-dose BM-MNC group at 90 days. Intra-arterial BM-MNC transplantation in patients with ischemic stroke seems to modulate early circulating miRNA-34a levels, which have been related to precursor cell migration in stroke and smaller infarct volumes.

Assessment of Intra-arterial Injected Autologous Bone Marrow Mononuclear Cell Distribution by Radioactive Labeling in Acute Ischemic Stroke

2007 ◽  
Vol 32 (11) ◽  
pp. 839-841 ◽  
Author(s):  
Patricia Lavatori Correa ◽  
Claudio T. Mesquita ◽  
Renata M. Felix ◽  
Jader C. Azevedo ◽  
Gustavo B. Barbirato ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Mononuclear Cell ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cell ◽  
Cell Distribution ◽  
Autologous Bone

The antidepressant effect of bone marrow mononuclear cell transplantation in chronic stress

2019 ◽  
Vol 33 (5) ◽  
pp. 632-639 ◽  
Author(s):  
Pedro Antônio Schmidt do Prado-Lima ◽  
Guilherme Ary Onsten ◽  
Gutierre Neves de Oliveira ◽  
Guilherme Camargo Brito ◽  
Isadora Machado Ghilardi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Dna Damage ◽  
Chronic Stress ◽  
Mononuclear Cell ◽  
Sucrose Preference ◽  
Control Group ◽  
Bone Marrow Mononuclear Cell ◽  
Anti Inflammatory ◽  
Inflammatory Effect ◽  
Damaged Dna

Background: Inflammation could be a risk factor for the development of depression and change the outcome of this common chronic-recurrent mental disorder. Aims: This study aimed to investigate if bone marrow mononuclear cell (BMMC) transplantation is effective in restoring sucrose preference in rats subjected to chronic stress (CS), if it has an anti-inflammatory effect and is able to restore damaged DNA. Methods: The effect of BMMC transplantation was studied in a controlled protocol (compared with a control group and a selective serotonin reuptake inhibitor escitalopram group) involving sucrose preference in CS in rats. Measurements were taken of the amygdala, hippocampus, frontal cortex, and other brain areas, the spleen and blood pro-inflammatory cytokines, namely interleukin-1β, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma, as well as anti-inflammatory cytokine interleukin-10. Finally, 8-hydroxy-2’-deoxyguanosine (a DNA damage marker) was determined. Results: BMMC transplantation was as effective as escitalopram in restoring sucrose preference. It also had an anti-inflammatory effect and slightly improved damaged DNA after one week. Conclusions: These findings suggest administration of BMMC in rats subjected to CS restores sucrose preference, resolves inflammation in both the peripheral and central nervous system, as well as diminishes DNA damage. This effect was similar to that of escitalopram, which is effective in the treatment of depressive patients.

Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke

2011 ◽  
Vol 6 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Valeria Battistella ◽  
Gabriel R de Freitas ◽  
Lea Mirian Barbosa da Fonseca ◽  
Daniel Mercante ◽  
Bianca Gutfilen ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Ischemic Stroke ◽  
Cell Transplantation ◽  
Mononuclear Cell ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cell ◽  
Autologous Bone

Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high‐risk myelodysplastic syndrome

2019 ◽  
Vol 102 (3) ◽  
pp. 218-226
Author(s):  
Marie Warny ◽  
Jens Helby ◽  
Henrik Sengeløv ◽  
Børge G. Nordestgaard ◽  
Henrik Birgens ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Acute Myeloid Leukaemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukaemia ◽  
Telomere Length ◽  
Mononuclear Cell ◽  
Bone Marrow Mononuclear Cell ◽  
Acute Myeloid

scholarly journals Efficacy of autologous bone marrow mononuclear cell transplantation in dogs with chronic spinal cord injury

2020 ◽  
Vol 10 (2) ◽  
pp. 206-215
Author(s):  
Katsutoshi Tamura ◽  
Noritaka Maeta
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Cell Transplantation ◽  
Mononuclear Cell ◽  
Motor Neurons ◽  
Research Work ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cell ◽  
Cord Injury

Background: Spinal cord injury (SCI) is relatively common in dogs and is a devastating condition involving loss of sensory neurons and motor  neurons. However, the main clinical protocol for the management of SCI is surgery to decompress and stabilize the vertebra. Cell transplantation therapy is a very promising strategy for the treatment of chronic SCI, but extensive preclinical and clinical research work remains.Aim: The aim of this study is to confirm the effect of bone marrow-derived mononuclear cell (BM-MNC) transplantation for chronic SCI in dogs.Methods: We tested the treatment efficiency of chronic SCI in 12 dogs using BM-MNC transplantation. Neurological evaluation used the Texas Spinal Cord Injury Scale (TSCIS). Concurrently, we characterized the transplanted cells by evaluation using quantitative real-time polymerase chain reaction, flow cytometry, and enzyme-linked immunosorbent assay.Result: All dogs had a pre-transplantation TSCIS score of 0. Two animals did not show any improvement in their final TSCIS scores. The remaining 10 dogs (83.4%) achieved improvement in the final TSCIS scores. Five of them (41.7%) regained ambulatory function with a TSCIS score greater than 10. We determined that canine BM-MNCs expressed hepatocyte growth factor (HGF) mRNA at higher levels than other cytokines, with significant  increases in HGF levels in cerebrospinal fluid within 48 hours after autologous BM-MNC transplantation into the subarachnoid space of the spinal dura matter in dogs.Conclusions: BM-MNC transplantation may be effective for at least some cases of chronic SCI. Keywords: Bone marrow-derived mononuclear cell, Cell therapy, Spinal cord injury.

Sign in / Sign up

Export Citation Format

Share Document